Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Tilray Brands Swings to Adjusted Loss in Fiscal 2027 Q1

Tilray Brands Swings to Adjusted Loss in Fiscal 2027 Q1

MT newswireMT newswire2026/10/08 11:47

07:47 AM EDT, 10/08/2026 (MT Newswires) -- Tilray Brands (TLRY.TO, TLRY) reported fiscal first quarter adjusted net loss per share of $0.02 on Thursday, compared with adjusted net income per share of $0.03 a year earlier. Net revenue increased to $257.1 million in the quarter-ended Aug. 31, 2026, compared with $209.5 million, a year-ago. Analysts expected revenue of $266.3 million. The company reaffirmed its fiscal year ending May 31, 2027, expectation to achieve adjusted EBITDA of $68 million to $75 million. US-listed shares of the company were last seen down 2.6% at $3.62 in pre-market trading.

07:47 AM EDT, 10/08/2026 (MT Newswires) -- Tilray Brands (TLRY.TO, TLRY) reported fiscal first quarter adjusted net loss per share of $0.02 on Thursday, compared with adjusted net income per share of $0.03 a year earlier. Net revenue increased to $257.1 million in the quarter-ended Aug. 31, 2026, compared with $209.5 million, a year-ago. Analysts expected revenue of $266.3 million. The company reaffirmed its fiscal year ending May 31, 2027, expectation to achieve adjusted EBITDA of $68 million to $75 million. US-listed shares of the company were last seen down 2.6% at $3.62 in pre-market trading.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss